Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise Limited is responsible for the commercialisation of University of Cambridge intellectual property and is a wholly owned subsidiary of the University. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and other related programmes.
The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing, company creation or consultancy. Income over the past three years exceeded £27 million, of which over £22 million was distributed to University academics and departments, with the remainder reinvested in patent assets, seed fund pools and support for knowledge and technology transfer services to the University.
The website contains information on technologies available for licensing and details of companies formed with technology arising from the University of Cambridge. Cambridge Enterprise is also responsible for the commercial licensing of research reagents owned by the University.
Cambridge Enterprise has announced the completion of a licensing agreement with Cantabio Pharmaceuticals, Inc. that gives the company access to intellectual property from research targeting the Tau protein for the treatment of “Tauopathies” such as Alzheimer’s disease (AD) and dementia.
8 September 2016Read in full
Cambridge postdocs are the best in their fields: young academic researchers with the potential to have world-changing impact. But all too often the walls of academia hinder dialogue between industry and researchers. When this happens, that world-changing potential goes unrealised. Cambridge Minds was created to fix that.
23 August 2016Read in full
Healthera Ltd, a provider of next-generation, pharmacy-integrated personal health management solutions, has secured seed investment from the University of Cambridge, the University of Cambridge Enterprise Fund III, FT Capital and high net worth individuals. The specific amounts are undisclosed.
18 August 2016Read in full
Cambridge Enterprise is delighted to announce that nine semi-finalist projects have been selected in the 2016 Entrepreneurial Postdocs of Cambridge (EPOC) business plan competition.
26 July 2016Read in full
A Cambridge spin-out has developed a completely new way of ventilating buildings that has the potential to reduce heating bills by as much as 50 percent while drastically reducing energy consumption. The natural ventilation technology concept exploits the heat produced by people, lights, IT and even sunlight, avoiding the wasteful use of radiators.
19 July 2016Read in full
8power Limited, a new company spun-out of the University of Cambridge to develop and commercialise novel technology for sensing and measurement in industrial applications, has received initial funding of approximately £700,000 from IP Group plc (LSE: IPO), the University of Cambridge and the University of Cambridge Enterprise Fund III, managed by Parkwalk Advisors.
1 July 2016Read in full
A lead-acid battery paste recycling technology that is cheaper and cleaner than traditional methods, developed by Dr RV Kumar and his research team of the Materials Science Department at the University of Cambridge, has been licensed to Aurelius Environmental (AE) in the West Midlands.
30 June 2016Read in full
A new collaboration between University of Cambridge researchers and global pharmaceutical company GlaxoSmithKline (GSK) has been established to discover and develop new medicines to treat HIV.
20 June 2016Read in full
Austria-based ams, a leading worldwide manufacturer of high performance sensor and analog solutions, has signed an agreement to acquire 100% of the shares in Cambridge CMOS Sensors Ltd (CCMOSS), the technology leader in micro hotplate structures for gas sensing and infrared applications, in an all-cash transaction.
16 June 2016Read in full
The Cambridge Enterprise film, #nextgreatidea, was awarded gold at the EVCOM Screen Awards 2016, held at Lindley Hall in Westminster.
10 May 2016Read in full
Technology Associate (Life Sciences)
Our Technology Associates play a key role in helping researchers develop their ideas, technologies and inventions into opportuni...
Salary: £0 - £0